<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896493</url>
  </required_header>
  <id_info>
    <org_study_id>BMT206</org_study_id>
    <secondary_id>SU-04062009-2138</secondary_id>
    <secondary_id>16213</secondary_id>
    <nct_id>NCT00896493</nct_id>
  </id_info>
  <brief_title>Ph II of Non-myeloablative Allogeneic Transplantation Using TLI &amp; ATG In Patients w/ Cutaneous T Cell Lymphoma</brief_title>
  <official_title>A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given
      that the median age at diagnosis is 55-60 years and frequently present compromised skin in
      these patients, which increases the risk of infection. Therefore, we propose a clinical study
      with allogeneic HSCT using a unique non-myeloablative preparative regimen, TLI/ATG, to treat
      advanced MF/SS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the graft versus lymphoma effect by monitoring rate of clinical response, event-free and overall survival.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence and extent of acute and chronic GVHD and time to engraftment.</measure>
    <time_frame>acute-first 100 days after transplant chronic-from 100days year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mycoses</condition>
  <condition>Sezary Syndrome</condition>
  <condition>Lymphoma, T-Cell, Cutaneous</condition>
  <condition>Bone Marrow Transplant Failure</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Cutaneous T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Total lymphoid irradiation &amp; anti-thymocyte immunoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>1.5 mg/kg x 5 days, IV</description>
    <arm_group_label>Total lymphoid irradiation &amp; anti-thymocyte immunoglobulin</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>5 mg/kg PO or IV</description>
    <arm_group_label>Total lymphoid irradiation &amp; anti-thymocyte immunoglobulin</arm_group_label>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        3.1 Inclusion Criteria

        3.1.1 Stage IIB-IV mycosis fungoides or Sezary syndrome, who have failed at least 1
        standard systemic therapy or are not candidates for standard therapy.

        3.1.2 Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center.

        3.1.4 Age &gt; 18 years and &lt;= 75 years.

        3.1.5 Karnofsky Performance Status &gt;= 70%.

        3.1.6 Corrected DLCO &gt;= 40%

        3.1.7 Left ventricle ejection fraction (LVEF) &gt; 30%.

        3.1.8 ALT and AST must be &lt;= 3X normal. Total bilirubin &lt;= 3 mg/dL unless hemolysis or
        Gilbert's disease.

        3.1.9 Estimated creatinine clearance &gt;= 50 ml/min.

        3.1.10 Have a related or unrelated HLA-identical donor or one antigen/allele mismatched in
        HLA-A, B, C or DRB1.

        3.1.11 Signed informed consent.

        3.3 Donor Inclusion Criteria

        3.3.1 Age &gt;=17.

        3.3.2 HIV seronegative.

        3.3.3 Signed informed consent.

        3.3.4 No contraindication to the administration of G-CSF.

        3.3.5 Willing to have a central venous catheter placed for apheresis if peripheral veins
        are inadequate.

        3.5 Enrollment

        Enrollment occurs when all eligibility criteria are met.

        Exclusion Criteria:

        3.2 Exclusion Criteria

        3.2.1 Uncontrolled active infection.

        3.2.2 Uncontrolled congestive heart failure or angina.

        3.2.3 Pregnancy or nursing patients will be excluded from the study.

        3.2.4 Those who are HIV-positive will be excluded from the study due to high risk of lethal
        infection after hematopoietic cell transplantation.

        3.2.5 No prior malignancy is allowed except adequately treated basal cell or squamous cell
        skin cancer, in situ cervical cancer or other cancer for which the patients has been
        disease-free for five years.

        3.4 Donor Exclusion Criteria

        3.4.1 Serious medical or psychological illness.

        3.4.2 Pregnant or lactating women are not eligible

        3.4.3 Prior malignancies within the last 5 years except for non-melanoma skin cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Kai Weng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Physician Referrals</last_name>
    <phone>(650) 723-0822</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Physician Referrals</last_name>
      <phone>650-723-0822</phone>
    </contact>
    <investigator>
      <last_name>Wen-Kai Weng</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ranjana Hira Advani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sally Arai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Benjamin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard T. Hoppe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura A Johnson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youn H Kim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Lowsky</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Miklos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert S Negrin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Anne Shizuru</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2009</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

